PR release

Transaction brings pioneering piezoelectric surgery, ultrasonic scaling and air-polishing technologies into HuFriedyGroup's global dental solutions portfolio

With a team of just 12 employees, the clinical AI company has grown largely through physician referrals, bringing total funding to $32 million

New offerings help eligible patients explore treatment, coverage and savings options, including Medicare GLP-1 Bridge participants and those with commercial insurance

The epilepsy market is expected to grow due to an increase in disease prevalence and the expected launch of emerging therapies, including Azetukalner (XEN1101; Xenon Pharmaceuticals), ABS-1230 (Actio Biosciences), BHV-7000 (Biohaven Pharmaceuticals), Relutrigine (PRAX-562; Praxis Precision Medicines), Zorevunersen (STK-001; Stoke Therapeutics), and others during the forecast period.

DELRAY BEACH, Fla. , Oct. 27, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Medical Device Contract Manufacturing Market is projected to reach USD 135.47 billion by 2031 from USD 85.59 billion in 2026, at a CAGR of 9.6% during the forecast period.

Suzanne Wallace appointed Vice President of Clinical and Market Development; Scott Tyler appointed Senior Director of Clinical Engineering and Development

Study will test whether living myeloma cells can be found and recovered from a blood sample, with the goal of giving doctors bone marrow-level insight from a blood draw.

Exploratory analysis presented at the ESMO Congress suggests changes in lactate dehydrogenase (LDH) measurements over time may complement imaging in assessing disease activity in glioblastoma

New Houston/Katy clinic expands access to medically supervised Narrowband UVB phototherapy, offering patients a drug-free treatment option for chronic inflammatory and autoimmune skin conditions.

Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China

STOCKHOLM , Oct. 27, 2026 /PRNewswire/ -- Capitainer, a Swedish provider of volumetric microsampling solutions, has reached an important milestone in its U.S. regulatory strategy with the first clinical sample collected as part of its study on HbA1c, a marker of long-term blood glucose levels, intended to support a planned FDA 510(k) submission.

SYDNEY , Oct. 27, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the registrational Phase III CLARIFY trial ( NCT06056830 ) [1] has dosed the planned target of 383 participants in the study.

As GLP-1 prescribing outpaces obesity medicine training, Proto360 Health gives physicians across specialties and corporate employers a dedicated care team that starts every patient with the same diagnostic assessment and uses clinical data to guide each phase of treatment.

Transaction reflects the successful execution of 5CP's value creation strategy and positions Radon for next phase of growth

Pioneer of prospective surveillance brings more than 25 years of research, health system implementation, policy leadership and clinical business experience to accelerate adoption of the SOZO ® platform in cancer survivorship care pathways

SAN DIEGO , Oct. 27, 2026 /PRNewswire/ -- SEKISUI Diagnostics, a global medical diagnostics manufacturer, has announced the launch of a 510(k) cleared rapid test to detect COVID-19 and Flu A&B in professional healthcare settings.

HENDERSON, Nev. , Oct. 27, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has executed a non-binding Letter of Intent ("LOI") with Missionpharma A/S , a Danish global leader in the sale and distribution of healthcare products and innovative solutions, impacting the lives of over 100 million patients annually, regarding the potential development and launch of Volition's prototype Lateral Flow Technology ("LFT") for NETosis.

First patient enrolled and treated at West Cancer Center in Tennessee, USA

New Ampa One feature will help clinicians keep the coil in position by automatically pausing brain stimulation when coil moves off target

Approximately 90% of pathology labs still rely on glass slides as diagnostic workloads surge 42%, creating diagnosis delays that cost patients time and health systems millions